Smartest Doc
FDA: Long-term use of Actos increases cancer risk Full Text
American Pharmacists Association News, 07/06/2011
FDA recently issued a drug safety communication warning patients and health professionals that use of pioglitazone (Actos—Takeda) for more than 1 year may be associated with an increased risk of bladder cancer. This information will be added to the Warnings and Precautions section of the drug label and to the patient Medication Guide for all drugs containing pioglitazone.